Le Lézard
Classified in: Covid-19 virus
Subject: MRR

U.S. Construction Market Report 2021: Key Trends and Opportunities to 2025


DUBLIN, Nov. 29, 2021 /PRNewswire/ -- The "Construction in the United States of America (USA) - Key Trends and Opportunities to 2025 (Q3 2021)" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The US construction industry is forecast to grow by 1.8% in 2021 and 3.7% in 2022, before it registers an annual average growth of 3.7% over the reminder of the forecast period.

The forecast assumes that the residential construction sector will continue to grow over the coming quarters despite the ongoing supply chain challenges, including the shortage of building materials and rising prices, lack of skilled labor and expensive land, which is adding to building costs for new homes, as well as causing project delays and boosting house price inflation.

The residential construction sector has been the star performer of the US economic recovery from the Coronavirus (COVID-19) crisis, posting double-digit growth rates since the third quarter of 2020, and making significant contributions to the rebound of the economy and overall construction industry. The sector remains supported by low mortgage rates, strong demand for bigger living spaces and a very low housing inventory in the market.

Following the Senate's overwhelming bipartisan approval on August 10th, 2021 of the long-awaited infrastructure spending bill, which includes long-term investments on transport, energy, utilities and climate-related initiatives, sentiment regarding the outlook for infrastructure and power sector has improved. While the new bill falls short of President Joe Biden's original US$2.3 trillion proposal, it includes US$550 billion in new federal spending to invest in various US infrastructure sectors over the next five years.

The report provides detailed market analysis, information and insights into the US construction industry, including:

This report provides a comprehensive analysis of the construction industry in the US. It provides:

For more information about this report visit https://www.researchandmarkets.com/r/pyiv0c

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets


These press releases may also interest you

at 01:20
Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specialized in thedevelopment oftherapeutics for age-related diseases, today annouces that it will change the ratio...

18 avr 2024
The report titled "Clinical Trials Matching Software Market by Functionality (Analytics & Reporting, Compliance Tracking, Data Management), Deployment (Cloud & Web Based, On-Premise), End-Use - Global Forecast 2024-2030" is now available on...

18 avr 2024
South Korea's biotechnology company Hyundai Bioscience (CEO Oh Sang-gi, www.hyundaibioscience.com) announced on April 15 that it would carry out global clinical tests aimed at treating all serotypes of Dengue virus infection....

18 avr 2024
The economic turmoil triggered by the COVID-19 pandemic has led to a sharp decrease in the number of self-employed individuals in the United States, with a 22% reduction...

18 avr 2024
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of common stock of QuidelOrtho Corporation between February 18, 2022 and April 1, 2024, both dates inclusive (the "Class...

18 avr 2024
Takeda (TSE:4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has approved ENTYVIO® (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn's disease (CD)...



News published on and distributed by: